Outside of big pharma, life remains tough for listed developers

Followers of the biotech market will be well aware of just how tough conditions for young developers are right now. That pain is not restricted to the small cap end of the market, Evaluate Vantage’s quarterly look at global drug stocks shows.

With the exception of big pharma all market cap brackets suffered serious declines over the first quarter, in both absolute terms and percentage-wise. And while it was the big names in Covid vaccines that suffered the steepest drops, investors walked away from plenty of other non-pandemic stories.